DANVERS, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Jan. 7, 2019--
Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies today reported preliminary, unaudited, third
quarter fiscal 2019 revenue of approximately $200.6 million, an increase
of 30% compared to revenue of $154.0 million for the same period of
Preliminary unaudited U.S. Impella® product revenue grew 27% to
approximately $165.7 million from $130.7 million in the prior fiscal
year. U.S. patient usage grew 24% in comparison with same period of
Outside the U.S., Impella product revenue for the quarter totaled
$27.5 million, an increase of 59% compared to revenue of $17.3
million during the same period of fiscal 2018, due to strength in
Germany and Japan.
The preliminary unaudited revenue results described in this press
release are estimates only and are subject to revision until the company
reports its full financial results for the third quarter of fiscal 2019
on January 31, 2019.
These preliminary results are being provided in advance of the company's
presentation at the 37th Annual J.P. Morgan Healthcare Conference at the
Westin St. Francis Hotel in San Francisco. Michael R. Minogue, Chairman,
President and Chief Executive Officer, Abiomed, will present at 5:00
p.m. PST / 8:00 p.m. EST on Monday, January 7, 2019.
A live webcast of the company's presentation at the conference will be
available via the link https://jpmorgan.metameetings.net/events/healthcare19/sessions/23805-abiomed-inc/webcast.
The webcast will also be available on the investor section of the
company's website at www.abiomed.com.
A replay of the webcast will be available for 90 days after the
FISCAL YEAR 2019 OUTLOOK
The company is increasing its 2019 revenue guidance to approximately
$780 million, from a range of $765 million to $770 million, an increase
in revenue of approximately 31% from the prior year. Other operating
details of third quarter fiscal 2019 will be provided on the company’s
earnings call on January 31, 2019.
EARNINGS CONFERENCE CALL DETAILS
The company will release full quarterly results for the third quarter of
fiscal 2019 via conference call at 8:00 a.m. EST on Thursday, January
31, 2019. The conference call releasing full quarterly results will be
hosted by Michael R. Minogue, Chairman, President and Chief Executive
Officer and Todd A. Trapp, Vice President and Chief Financial Officer.
To listen to the call live, please tune into the webcast via https://edge.media-server.com/m6/p/kxrqfpvzor dial (855) 212-2361; the international number is (678)
809-1538. A replay of this conference call will be available beginning
at 12:00 p.m. ESTJanuary 31, 2019 through 12:00 p.m. EST on February 7,
2019. The replay phone number is (855) 859-2056; the international
number is (404) 537-3406. The replay access code is 2499899.
The ABIOMED logo, ABIOMED, IMPELLA, IMPELLA 2.5, IMPELLA 5.0, IMPELLA
LD, IMPELLA CP, IMPELLA RP, IMPELLA BTR, IMPELLA 5.5, and IMPELLA ECP
are registered marks or trademarks of ABIOMED, Inc., and are registered
in the U.S. and certain foreign countries. AB5000 and cVAD REGISTRY,
Recovering hearts. Saving lives. are trademarks of ABIOMED, Inc.
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of
medical devices that provide circulatory support. Our products are
designed to enable the heart to rest by improving blood flow and/or
performing the pumping of the heart. For additional information, please
This release contains forward-looking statements, including statements
regarding development of Abiomed's existing and new products, the
company's progress toward commercial growth, and future opportunities
and expected regulatory approvals. The company's actual results may
differ materially from those anticipated in these forward-looking
statements based upon a number of factors, including uncertainties
associated with development, testing and related regulatory approvals,
including the unpredictability of future operating results, complex
manufacturing, high quality requirements, dependence on limited sources
of supply, competition, technological change, government regulation,
litigation matters, future capital needs and uncertainty of additional
financing, and other risks and challenges detailed in the company's
filings with the Securities and Exchange Commission, including the most
recently filed Annual Report on Form 10-K and Quarterly Report on Form
10-Q. Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this
release. The company undertakes no obligation to publicly release the
results of any revisions to these forward-looking statements that may be
made to reflect events or circumstances that occur after the date of
this release or to reflect the occurrence of unanticipated events.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190107005335/en/
Source: Abiomed, Inc.
Director, Investor Relations
Director, Communications & Public Relations